Marco Filipuzzi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Marco Filipuzzi has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
A. Aloisio
INFN Sezione di Napoli
48 shared publicationsA. Angerami
Columbia University
48 shared publicationsA. Annovi
INFN Sezione di Pisa
48 shared publicationsA. Antonov
National Research Nuclear University MEPhI
48 shared publicationsA. Artamonov
Institute for Theoretical and Experimental Physics (ITEP)
48 shared publicationsA. Ashkenazi
Tel Aviv University
48 shared publications
Latest Publications
- Open Access
- 12 May 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1
Correction: Senataxin prevents replicative stress induced by the Myc oncogene
- 12 May 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1
Open AccessCorrection: Senataxin prevents replicative stress induced by the Myc oncogene
- Open Access
- 19 March 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-15
Senataxin prevents replicative stress induced by the Myc oncogene
Replicative stress (RS) is emerging as a promising therapeutic target in oncology, yet full exploitation of its potential requires a detailed understanding of the mechanisms and genes involved. Here, we investigated the RNA helicase Senataxin (SETX), an enzyme that resolves RNA-DNA hybrids and R-loops, to address its role in preventing RS by oncogenic Myc. Upon Myc activation, silencing of SETX led to selective engagement of the DNA damage response (DDR) and robust cytotoxicity. Pharmacological dissection of the upstream kinases regulating the DDR uncovered a protective role of the ATR pathway, that once inhibited, boosted SETX driven-DDR. While SETX loss did not lead to a genome-wide increase of R-loops, mechanistic analyses revealed enhanced R-loops localized at DDR-foci and newly replicated genomic loci, compatible with a selective role of SETX in resolving RNA-DNA hybrids to alleviate Myc-induced RS. Genome-wide mapping of DNA double-strand breaks confirmed that SETX silencing exacerbated DNA damage at transcription-replication conflict (TRC) regions at early replicated sites. We propose that SETX prevents Myc-induced TRCs by resolving transcription-associated R-loops that encounter the replisome. The identification of SETX as a genetic liability of oncogenic Myc opens up new therapeutic options against aggressive Myc-driven tumors.
- 19 March 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-15
Open AccessSenataxin prevents replicative stress induced by the Myc oncogene
Replicative stress (RS) is emerging as a promising therapeutic target in oncology, yet full exploitation of its potential requires a detailed understanding of the mechanisms and genes involved. Here, we investigated the RNA helicase Senataxin (SETX), an enzyme that resolves RNA-DNA hybrids and R-loops, to address its role in preventing RS by oncogenic Myc. Upon Myc activation, silencing of SETX led to selective engagement of the DNA damage response (DDR) and robust cytotoxicity. Pharmacological dissection of the upstream kinases regulating the DDR uncovered a protective role of the ATR pathway, that once inhibited, boosted SETX driven-DDR. While SETX loss did not lead to a genome-wide increase of R-loops, mechanistic analyses revealed enhanced R-loops localized at DDR-foci and newly replicated genomic loci, compatible with a selective role of SETX in resolving RNA-DNA hybrids to alleviate Myc-induced RS. Genome-wide mapping of DNA double-strand breaks confirmed that SETX silencing exacerbated DNA damage at transcription-replication conflict (TRC) regions at early replicated sites. We propose that SETX prevents Myc-induced TRCs by resolving transcription-associated R-loops that encounter the replisome. The identification of SETX as a genetic liability of oncogenic Myc opens up new therapeutic options against aggressive Myc-driven tumors.
- Open Access
Polycomb Group Ring Finger Protein 6 suppresses Myc-induced lymphomagenesis
Max is an obligate dimerization partner for the Myc transcription factors and for several repressors, such as Mnt, Mxd1-4 and Mga, collectively thought to antagonize Myc function in transcription and oncogenesis. Mga, in particular, is part of the variant Polycomb group repressive complex PRC1.6. Here, we show that ablation of the distinct PRC1.6 subunit Pcgf6 – but not Mga – accelerates Myc-induced lymphomagenesis in Eµ- myc transgenic mice. Unexpectedly, however, Pcgf6 loss shows no significant impact on transcriptional profiles, in neither pre-tumoral B-cells, nor lymphomas. Altogether, these data unravel an unforeseen, Mga- and PRC1.6-independent tumor suppressor activity of Pcgf6.
Open AccessPolycomb Group Ring Finger Protein 6 suppresses Myc-induced lymphomagenesis
Max is an obligate dimerization partner for the Myc transcription factors and for several repressors, such as Mnt, Mxd1-4 and Mga, collectively thought to antagonize Myc function in transcription and oncogenesis. Mga, in particular, is part of the variant Polycomb group repressive complex PRC1.6. Here, we show that ablation of the distinct PRC1.6 subunit Pcgf6 – but not Mga – accelerates Myc-induced lymphomagenesis in Eµ- myc transgenic mice. Unexpectedly, however, Pcgf6 loss shows no significant impact on transcriptional profiles, in neither pre-tumoral B-cells, nor lymphomas. Altogether, these data unravel an unforeseen, Mga- and PRC1.6-independent tumor suppressor activity of Pcgf6.
- 1 April 2021
- Published by Springer Nature in The EMBO Journal
- Vol. 40 (10) , e105464
Integrated requirement of non‐specific and sequence‐specific DNA binding in Myc‐driven transcription
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
- 1 April 2021
- Published by Springer Nature in The EMBO Journal
- Vol. 40 (10) , e105464
Integrated requirement of non‐specific and sequence‐specific DNA binding in Myc‐driven transcription
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
- 22 January 2020
- Published by Wolters Kluwer Health in Hepatology
- Vol. 72 (4) , 1430-1443
Cooperation Between MYC and β‐Catenin in Liver Tumorigenesis Requires Yap/Taz
Background and Aims: Activation of MYC and catenin beta‐1 (CTNNB1, encoding β‐catenin) can co‐occur in liver cancer, but how these oncogenes cooperate in tumorigenesis remains unclear. Approach and Results: We generated a mouse model allowing conditional activation of MYC and WNT/β‐catenin signaling (through either β‐catenin activation or loss of APC ‐ adenomatous polyposis coli) upon expression of CRE recombinase in the liver and monitored their effects on hepatocyte proliferation, apoptosis, gene expression profiles, and tumorigenesis. Activation of WNT/β‐catenin signaling strongly accelerated MYC‐driven carcinogenesis in the liver. Both pathways also cooperated in promoting cellular transformation in vitro, demonstrating their cell‐autonomous action. Short‐term induction of MYC and β‐catenin in hepatocytes, followed by RNA‐sequencing profiling, allowed the identification of a “Myc/β‐catenin signature,” composed of a discrete set of Myc‐activated genes whose expression increased in the presence of active β‐catenin. Notably, this signature enriched for targets of Yes‐associated protein (Yap) and transcriptional coactivator with PDZ‐binding motif (Taz), two transcriptional coactivators known to be activated by WNT/β‐catenin signaling and to cooperate with MYC in mitogenic activation and liver transformation. Consistent with these regulatory connections, Yap/Taz accumulated upon Myc/β‐catenin activation and were required not only for the ensuing proliferative response, but also for tumor cell growth and survival. Finally, the Myc/β‐catenin signature was enriched in a subset of human hepatocellular carcinomas characterized by comparatively poor prognosis. Conclusions: Myc and β‐catenin show a strong cooperative action in liver carcinogenesis, with Yap and Taz serving as mediators of this effect. These findings warrant efforts toward therapeutic targeting of Yap/Taz in aggressive liver tumors marked by elevated Myc/β‐catenin activity.
- 22 January 2020
- Published by Wolters Kluwer Health in Hepatology
- Vol. 72 (4) , 1430-1443
Cooperation Between MYC and β‐Catenin in Liver Tumorigenesis Requires Yap/Taz
Background and Aims: Activation of MYC and catenin beta‐1 (CTNNB1, encoding β‐catenin) can co‐occur in liver cancer, but how these oncogenes cooperate in tumorigenesis remains unclear. Approach and Results: We generated a mouse model allowing conditional activation of MYC and WNT/β‐catenin signaling (through either β‐catenin activation or loss of APC ‐ adenomatous polyposis coli) upon expression of CRE recombinase in the liver and monitored their effects on hepatocyte proliferation, apoptosis, gene expression profiles, and tumorigenesis. Activation of WNT/β‐catenin signaling strongly accelerated MYC‐driven carcinogenesis in the liver. Both pathways also cooperated in promoting cellular transformation in vitro, demonstrating their cell‐autonomous action. Short‐term induction of MYC and β‐catenin in hepatocytes, followed by RNA‐sequencing profiling, allowed the identification of a “Myc/β‐catenin signature,” composed of a discrete set of Myc‐activated genes whose expression increased in the presence of active β‐catenin. Notably, this signature enriched for targets of Yes‐associated protein (Yap) and transcriptional coactivator with PDZ‐binding motif (Taz), two transcriptional coactivators known to be activated by WNT/β‐catenin signaling and to cooperate with MYC in mitogenic activation and liver transformation. Consistent with these regulatory connections, Yap/Taz accumulated upon Myc/β‐catenin activation and were required not only for the ensuing proliferative response, but also for tumor cell growth and survival. Finally, the Myc/β‐catenin signature was enriched in a subset of human hepatocellular carcinomas characterized by comparatively poor prognosis. Conclusions: Myc and β‐catenin show a strong cooperative action in liver carcinogenesis, with Yap and Taz serving as mediators of this effect. These findings warrant efforts toward therapeutic targeting of Yap/Taz in aggressive liver tumors marked by elevated Myc/β‐catenin activity.
- Open Access
- 25 October 2019
- Published by Cold Spring Harbor Laboratory in bioRxiv
- p. 819631
Cooperation between MYC and β-catenin in liver tumorigenesis requires Yap/Taz
Background & Aims: Activation of MYC and CTNNB1 (encoding β-catenin) can co-occur in liver cancer, but how these oncogenes cooperate in tumorigenesis remains unclear.Approach & Results: We generated a mouse model allowing conditional activation of MYC and WNT/β-catenin signaling (through either β-catenin activation or Apc loss) upon expression of CRE recombinase in the liver, and monitored their effects on hepatocyte proliferation, apoptosis, gene expression profiles and tumorigenesis. Conditional activation of WNT/β-catenin signaling strongly accelerated MYC-driven carcinogenesis in the mouse liver. Both pathways also cooperated in promoting cellular transformation in vitro, demonstrating their cell-autonomous action. Short-term induction of MYC and β-catenin in hepatocytes followed by RNA-seq profiling allowed the identification of a “Myc/β-catenin signature”, composed of a discrete set of Myc-activated genes whose expression increased in presence of active β-catenin. Notably this signature enriched for targets of Yap and Taz, two transcriptional co-activators known to be activated by WNT/β-catenin signaling, and to cooperate with MYC in mitogenic activation and liver transformation. Consistent with these regulatory connections, Yap/Taz accumulated upon Myc/β-catenin activation and were required not only for the ensuing proliferative response, but also for tumor cell growth and survival. Finally, the Myc/β-catenin signature was enriched in a subset of human hepatocellular carcinomas characterized by comparatively poor prognosis.Conclusions: Yap and Taz mediate the cooperative action of Myc and β-catenin in liver tumorigenesis. This warrants efforts toward therapeutic targeting of Yap/Taz in aggressive liver tumors marked by elevated Myc/β-catenin activity.
- 25 October 2019
- Published by Cold Spring Harbor Laboratory in bioRxiv
- p. 819631
Open AccessCooperation between MYC and β-catenin in liver tumorigenesis requires Yap/Taz
Background & Aims: Activation of MYC and CTNNB1 (encoding β-catenin) can co-occur in liver cancer, but how these oncogenes cooperate in tumorigenesis remains unclear.Approach & Results: We generated a mouse model allowing conditional activation of MYC and WNT/β-catenin signaling (through either β-catenin activation or Apc loss) upon expression of CRE recombinase in the liver, and monitored their effects on hepatocyte proliferation, apoptosis, gene expression profiles and tumorigenesis. Conditional activation of WNT/β-catenin signaling strongly accelerated MYC-driven carcinogenesis in the mouse liver. Both pathways also cooperated in promoting cellular transformation in vitro, demonstrating their cell-autonomous action. Short-term induction of MYC and β-catenin in hepatocytes followed by RNA-seq profiling allowed the identification of a “Myc/β-catenin signature”, composed of a discrete set of Myc-activated genes whose expression increased in presence of active β-catenin. Notably this signature enriched for targets of Yap and Taz, two transcriptional co-activators known to be activated by WNT/β-catenin signaling, and to cooperate with MYC in mitogenic activation and liver transformation. Consistent with these regulatory connections, Yap/Taz accumulated upon Myc/β-catenin activation and were required not only for the ensuing proliferative response, but also for tumor cell growth and survival. Finally, the Myc/β-catenin signature was enriched in a subset of human hepatocellular carcinomas characterized by comparatively poor prognosis.Conclusions: Yap and Taz mediate the cooperative action of Myc and β-catenin in liver tumorigenesis. This warrants efforts toward therapeutic targeting of Yap/Taz in aggressive liver tumors marked by elevated Myc/β-catenin activity.
- Open Access
- 22 August 2019
- Published by Springer Nature in Journal of High Energy Physics
- Vol. 2019 (8) , 121
Erratum to: Search for supersymmetry in final states with two same-sign or three leptons and jets using 36 fb−1 of $ \sqrt{s} $ = 13 TeV pp collision data with the ATLAS detectorOne correction is made to the figure 4e of the paper.
- 22 August 2019
- Published by Springer Nature in Journal of High Energy Physics
- Vol. 2019 (8) , 121
Open AccessErratum to: Search for supersymmetry in final states with two same-sign or three leptons and jets using 36 fb−1 of $ \sqrt{s} $ = 13 TeV pp collision data with the ATLAS detectorOne correction is made to the figure 4e of the paper.
- 23 July 2019
- Published by Springer Nature in EMBO Reports
- Vol. 20 (9) , e47987
An early Myc‐dependent transcriptional program orchestrates cell growth during B‐cell activation
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
- 23 July 2019
- Published by Springer Nature in EMBO Reports
- Vol. 20 (9) , e47987
An early Myc‐dependent transcriptional program orchestrates cell growth during B‐cell activation
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
- Open Access
- 9 January 2019
- Published by Springer Nature in The European Physical Journal C
- Vol. 79 (1) , 19
Erratum to: Measurement of the W boson polarisation in $t\bar{t}$ t t ¯ events from pp collisions at $\sqrt{s} = 8~\hbox {TeV}$ s = 8 TeV in the lepton + jets channel with ATLAS- 9 January 2019
- Published by Springer Nature in The European Physical Journal C
- Vol. 79 (1) , 19
Open AccessErratum to: Measurement of the W boson polarisation in $t\bar{t}$ t t ¯ events from pp collisions at $\sqrt{s} = 8~\hbox {TeV}$ s = 8 TeV in the lepton + jets channel with ATLAS - Open Access
- 1 January 2019
- Published by Elsevier in Physics Letters B
- Vol. 788, 316-335
Search for light resonances decaying to boosted quark pairs and produced in association with a photon or a jet in proton–proton collisions at with the ATLAS detector- 1 January 2019
- Published by Elsevier in Physics Letters B
- Vol. 788, 316-335
Open AccessSearch for light resonances decaying to boosted quark pairs and produced in association with a photon or a jet in proton–proton collisions at with the ATLAS detector